EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against other stocks that Jim Cramer discussed recently. Jim Cramer kicked off his latest ...

Matteo Paz built a machine-learning algorithm in high school to analyze heaps of data for NASA. He just won a $250,000 ...

DURHAM, N.C. (WTVD) -- Ava Grace Cummings is still on cloud nine after placing 2nd in the 2025 Regeneron Science Talent Search. The Johnston County teenager is a senior at the North Carolina ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncology pipeline. New data from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

When Matteo Paz scored a high school internship at the California Institute of Technology, the scientists there gave him the daunting task of manually sorting reams of data from a NASA mission.